

```

chain nodes :
  13 14 35 39 40 42
ring nodes :
  1 2 3 4 5 6 7 8 9 10 11 12 15 16 17 18 19 20 23 24 25 26 27 28 29 30
  31 32 33 34 43 44 45 46 47 48
chain bonds :
  1-13 8-13 14-17 14-39 23-35 30-35 40-42 42-44
ring bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20 16-17 17-18
  18-19 19-20 23-24 23-28 24-25 25-26 26-27 27-28 29-30 29-34 30-31 31-32 32-33
  33-34 43-44 43-48 44-45 45-46 46-47 47-48
exact/norm bonds :
  1-13 8-13 14-17 14-39 23-35 30-35
exact bonds :
  40-42 42-44
normalized bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20 16-17 17-18
  18-19 19-20 23-24 23-28 24-25 25-26 26-27 27-28 29-30 29-34 30-31 31-32 32-33
  33-34 43-44 43-48 44-45 45-46 46-47 47-48
isolated ring systems :
  containing 1 : 7 : 15 : 23 : 29 : 43 :

```

G1:[*1],[*2]

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 23:CLASS
24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom
34:Atom 35:CLASS 39:CLASS 40:CLASS 41:Atom 42:CLASS 43:Atom 44:Atom 45:Atom 46:Atom
47:Atom 48:Atom

```

Generic attributes :

```

14:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7

```

Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic

Element Count :

Node 14: Limited

C,C3


N,N2

O,O0

S,S0

=>

Uploading C:\Program Files\Stnexp\Queries\10584828.str



chain nodes :

13 14

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 16 17 18 19 20 21

chain bonds :

1-13 8-13 14-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 16-17 16-21
17-18 18-19 19-20 20-21

exact/norm bonds :

1-13 8-13 14-18

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 16-17 16-21
17-18 18-19 19-20 20-21

isolated ring systems :

containing 1 : 7 : 16 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom

Generic attributes :

14:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : 2 or more

Type of Ring System : Monocyclic

Element Count :
 Node 14: Limited
 C,C3
 N,N2
 O,O0
 S,S0

L1 STRUCTURE UPLOADED

=> d l1
 L1 HAS NO ANSWERS
 L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
 SAMPLE SEARCH INITIATED 20:42:20 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 11518 TO ITERATE

17.4% PROCESSED 2000 ITERATIONS 45 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 223928 TO 236792
 PROJECTED ANSWERS: 4218 TO 6148

L2 45 SEA SSS SAM L1

=> =>
 Uploading C:\Program Files\Stnexp\Queries\10584828 (a).str



chain nodes :

13 14 35 38 39 40 41 43 44 46

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 15 16 17 18 19 20 23 24 25 26 27
28 29 30 31 32 33 34 47 48 49 50 51 52

chain bonds :

1-13 4-39 5-38 8-13 14-17 14-43 23-35 25-41 27-40 30-35 44-46 46-48

ring bonds :

10/584,828

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20
16-17 17-18 18-19 19-20 23-24 23-28 24-25 25-26 26-27 27-28 29-30 29-34
30-31 31-32 32-33 33-34 47-48 47-52 48-49 49-50 50-51 51-52
exact/norm bonds :
1-13 8-13 14-17 14-43 23-35 30-35
exact bonds :
4-39 5-38 25-41 27-40 44-46 46-48
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20
16-17 17-18 18-19 19-20 23-24 23-28 24-25 25-26 26-27 27-28 29-30 29-34
30-31 31-32 32-33 33-34 47-48 47-52 48-49 49-50 50-51 51-52
isolated ring systems :
containing 1 : 7 : 15 : 23 : 29 : 47 :

G1:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:Atom 32:Atom 33:Atom 34:Atom 35:CLASS 38:CLASS 39:CLASS 40:CLASS
41:CLASS 43:CLASS 44:CLASS 45:Atom 46:CLASS 47:Atom 48:Atom 49:Atom 50:Atom
51:Atom 52:Atom

Generic attributes :

14:

Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic

Element Count :

Node 14: Limited

C,C3
N,N2
O,O0
S,S0

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 13 sss sam

SAMPLE SEARCH INITIATED 20:46:19 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2058 TO ITERATE

97.2% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 38439 TO 43881
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> =>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.35	4.41

FILE 'REGISTRY' ENTERED AT 20:49:54 ON 25 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAY 2009 HIGHEST RN 1148627-94-4
DICTIONARY FILE UPDATES: 24 MAY 2009 HIGHEST RN 1148627-94-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10584828 (b).str



chain nodes :

13 14 35 39 40 42

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 15 16 17 18 19 20 23 24 25 26 27
28 29 30 31 32 33 34 43 44 45 46 47 48

chain bonds :

1-13 8-13 14-17 14-39 23-35 30-35 40-42 42-44

ring bonds :

10/584,828

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20
16-17 17-18 18-19 19-20 23-24 23-28 24-25 25-26 26-27 27-28 29-30 29-34
30-31 31-32 32-33 33-34 43-44 43-48 44-45 45-46 46-47 47-48
exact/norm bonds :
1-13 8-13 14-17 14-39 23-35 30-35
exact bonds :
40-42 42-44
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20
16-17 17-18 18-19 19-20 23-24 23-28 24-25 25-26 26-27 27-28 29-30 29-34
30-31 31-32 32-33 33-34 43-44 43-48 44-45 45-46 46-47 47-48
isolated ring systems :
containing 1 : 7 : 15 : 23 : 29 : 43 :

G1:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:Atom 32:Atom 33:Atom 34:Atom 35:CLASS 39:CLASS 40:CLASS 41:Atom 42:CLASS
43:Atom 44:Atom 45:Atom 46:Atom 47:Atom 48:Atom

Generic attributes :

14:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : 2 or more

Type of Ring System : Monocyclic

Element Count :

Node 14: Limited

C,C3

N,N2

O,O0

S,S0

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 15 sss sam

SAMPLE SEARCH INITIATED 20:50:19 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2058 TO ITERATE

10/584,828

```

97.2% PROCESSED      2000 ITERATIONS                      0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

```

```

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   38439 TO    43881
PROJECTED ANSWERS:      0 TO      0

```

L6 0 SEA SSS SAM L5

```
=> s 15 sss ful
FULL SEARCH INITIATED 20:50:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      41820 TO ITERATE
```

```
100.0% PROCESSED      41820 ITERATIONS                      10 ANSWERS
SEARCH TIME: 00.00.03
```

L7 10 SEA SSS FUL L5

$$\begin{array}{ccc} \Rightarrow & \Rightarrow & s \quad 17 \\ L8 & & 2 \quad L7 \end{array}$$

```
=> d 18 1-2 bib,ab,hitr
```

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:673285 CAPLUS
 DN 143:172889
 TI Preparation of pyrazolyl-pyrimidinyl-amine derivatives as IGF-1R inhibitors
 IN Garcia-Echeverria, Carlos
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DT Patent Applicant's
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068452	A1	20050728	WO 2005-EP93	20050107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005205118	A1	20050728	AU 2005-205118	20050107
AU 2005205118	B2	20090226		
CA 2551948	A1	20050728	CA 2005-2551948	20050107
EP 1706400	A1	20061004	EP 2005-700746	20050107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1906188	A	20070131	CN 2005-80001977	20050107
BR 2005006760	A	20070522	BR 2005-6760	20050107
JP 2007517825	T	20070705	JP 2006-548229	20050107
IN 2006CN02492	A	20070608	IN 2006-CN2492	20060706
MX 2006007820	A	20060901	MX 2006-7820	20060707
KR 2006127032	A	20061211	KR 2006-713681	20060707
US 2004-535626P	P	20040109	provisional priority document	
WO 2005-EP93	W	20050107		

OS CASREACT 143:172889; MARPAT 143:172889

AB Title compds. I [m = 1-5; R1 = alkylsulfonyl, (un)substituted aminosulfonyl, amino, etc. or two vicinal R1 together with the Ph carbon that they are attached to form heterocyclic ring; R2 = H, (un)substituted alkyl or heterocycle; Z = benzyloxy with provisions] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of IGF-1R. Thus, e.g., II was prepared by cyclization of 1-(3-benzyloxy-phenyl)-2-(2-chloro-pyrimidin-4-yl)-3-dimethylamino-propenone (preparation given) with hydrazine monohydrate and subsequent couplings with 4-amino-benzoic acid and pyrrolidine. The efficacy of I as inhibitors of IGF-1R tyrosine kinase activity was demonstrated using a cellular "Capture ELISA" assay and it was revealed that compds. of the invention displayed IC50 values in the range of 5 nM to 1µM. I as inhibitors of IGF-1R should prove useful in the treatment of proliferative disease. Pharmaceutical compns. comprising I are disclosed.


IT 646525-40-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(compound excluded from invention; preparation of
pyrazolyl-pyrimidinyl-amine
derivs. as IGF-1R inhibitors)

RN 646525-40-8 CAPLUS

CN 2-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-4-[3-[4-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]- (CA INDEX NAME)



IT 860629-83-0P 860629-84-1P 860629-85-2P


860629-86-3P 860629-87-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolyl-pyrimidinyl-amine derivs. as IGF-1R inhibitors)


RN 860629-83-0 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]-N-[4-(1-pyrrolidinylmethyl)phenyl]- (CA INDEX NAME)




RN 860629-84-1 CAPLUS

CN 2-Pyrimidinamine, N-[4-[(dimethylamino)methyl]phenyl]-4-[3-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 860629-85-2 CAPLUS

CN Methanone, (4-methyl-1-piperazinyl)[4-[[4-[3-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 860629-86-3 CAPLUS

CN 2-Pyrimidinamine, N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-4-[3-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 860629-87-4 CAPLUS

CN Benzamide, 4-[[4-[3-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)




6 (5)

IT 860629-91-0P 860629-92-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrazolyl-pyrimidinyl-amine derivs. as IGF-1R inhibitors)
 RN 860629-91-0 CAPLUS
 CN Benzoic acid, 4-[[4-[3-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]-2-
 pyrimidinyl]amino]- (CA INDEX NAME)



RN 860629-92-1 CAPLUS
 CN Methanone, [4-[[4-[3-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]-2-
 pyrimidinyl]amino]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/584,828

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:41464 CAPLUS
 DN 140:111424
 TI Preparation of phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amines
 as protein tyrosine kinase inhibitors
 IN Furet, Pascal; Imbach, Patricia; Ramsey, Timothy Michael; Schlapbach,
 Achim; Scholz, Dieter; Caravatti, Giorgio
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005282	A1	20040115	WO 2003-EP7350	20030708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2491635	A1	20040115	CA 2003-2491635	20030708
AU 2003249993	A1	20040123	AU 2003-249993	20030708
EP 1521749	A1	20050413	EP 2003-762663	20030708
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012573	A	20050426	BR 2003-12573	20030708
CN 1668610	A	20050914	CN 2003-816383	20030708
CN 1330643	C	20070808		
JP 2006501183	T	20060112	JP 2004-518751	20030708
US 20060106027	A1	20060518	US 2005-520567	20050824
PRAI GB 2002-15844	A	20020709		
WO 2003-EP7350	W	20030708		

103 based on
102(e) date

OS MARPAT 140:111424

AB The title compds. [I; m = 1-5; R1 = alkylsulfonyl, (un)substituted
 aminosulfonyl, amino, etc.; R2 = H, (un)substituted alkyl, heterocyclyl;
 R3 = H, (un)substituted Ph; R31 = H if R3 = (un)substituted Ph or R31 =
 (un)substituted Ph if R3 = H; with the proviso], useful for treating
 diseases which respond to an inhibition of a protein tyrosine kinase, were
 prepared and formulated. Thus, reacting
 2-chloro-4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyrimidine with
 4-(4-methylpiperazin-1-yl)phenylamine afforded I [R1 =
 4-(4-methylpiperazin-1-yl); m = 1; R2 = H; R3 = 4-ClC6H4; R31 = H] which
 showed IC50 of 0.018 μ M, 0.023 μ M, and 0.01 μ M against EGF-R
 (HER-1), ErbB-2 (HER-2) and VEGF receptor (KDR), resp. The invention
 relates also to pharmaceutical compns. comprising the compds. I and to the
 use of such derivs. - alone or in combination with one or more other
 pharmaceutically active compds. - for the preparation of pharmaceutical compns.
 for the treatment especially of a proliferative disease, such as a tumor.


IT 646525-40-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

10/584,828

(preparation of phenyl[4-(3-phenyl-1H-pyrazol-4-yl)pyrimidin-2-yl]amines as protein tyrosine kinase inhibitors)

RN 646525-40-8 CAPLUS

CN 2-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-4-[3-[4-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]- (CA INDEX NAME)



proviso compound

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/584,828

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

11.78

202.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.64

-1.64

STN INTERNATIONAL LOGOFF AT 20:50:56 ON 25 MAY 2009